The National Stem Cell Foundation funded a 12-person clinical trial conducted by Dr. Michelle Fanale at the MD Anderson Cancer Center to test a multi-drug therapy option for patients with resistant lymphoma.
Four patients in the trial with resistant T-cell lymphoma had remarkable outcomes – one participant became cancer free and all three of the other participants with resistant T-cell lymphoma responded to treatment.
Dr. Fanale graduated from Rutgers University with a degree in Molecular Biology/Biochemistry and Psychology, then further studied at the University of Medicine and Dentistry in Newark, NJ before entering residency at the Mayo Clinic and then pursuing a Medical Oncology and Hematology Fellowship at MD Anderson Cancer Center.
She has clinical and research interests in Hodgkin’s disease, Burkitt lymphoma, and other c-MYC positive lymphomas, and HIV-associated lymphomas. Within these lymphoma subtypes she seeks to develop new therapies which can first be evaluated in relapsed/refractory disease and then integrated into earlier lines of therapy both in combination with each other and with chemotherapy.